The board of directors of Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) approved the sale of a 7.84% stake or 9,609,571 equity shares, in Glenmark Life Sciences Limited (NSEI:GLS), as stated in its filing to the exchanges on 10 July 2024. The stake sale will be done through the stock exchanges via an offer for sale (OFS). The decision was made at a meeting held on 10 July 2024, and the company informed about the development aftermarket hours.